close

Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Its orally-available drugs in clinical development include Sapacitabine (CYC682), an oral nucleoside analogue, which is in phase II studies for the treatment of hematological malignancies, such as acute myeloid leukemia in the elderly, myelodysplastic syndromes, cutaneous T-cell lymphoma, and lung cancer; Seliciclib (CYC202), a CDK (cyclin dependent kinase) inhibitor, which is in phase II studies for the treatment of lung cancer and nasopharyngeal cancer; and CYC116, an Aurora kinase and VEGFR2 inhibitor that is in phase I studies for patients with solid tumors. The company, through its subsidiary, ALIGN Pharmaceuticals, LLC, markets directly Xclair Cream for radiation dermatitis, as well as Numoisyn Liquid and Numoisyn Lozenges for xerostomia in the United States. It focuses on building a diversified biopharmaceutical business focused in hematology, oncology, and other therapeutic areas based on a portfolio of commercial products and a development pipeline of novel drug candidates. The company was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	0.62
Volume	143692
Volume Avg	324016
52 Week High	1.84
52 Week Low	0.36
PE	N/A
PE (group average)	39
EPS Year	-0.32
EPS change Q/Q	-42.86%
EPS change Q/Q Yr ago	-44.44%
EPS change Q/Q next Q est	100%
EPS change Y/Y	-91.3%
REV change Q/Q	100%
REV change Q/Q Yr ago	-33.33%
EPS next Q est	0.00
EPS next Y est	-0.33
Divident Annual	0.00
Dividend Yield	0%